natgillin/translations-raw huggingface dataset:
Translarna is a medicine that is used to treat patients aged 2 years and older with Duchenne muscular dystrophy who are able to walk. 
Translarna je zdravilo, ki se uporablja za zdravljenje bolnikov z Duchennovo mišično distrofijo, ki so starejši od dveh let in lahko hodijo.
Translarna is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation') in the dystrophin gene. 
Zdravilo Translarna se uporablja pri majhni skupini bolnikov, pri katerih je bolezen posledica posebne genetske okvare (imenovane „nesmiselna mutacija“) gena za distrofin.
Translarna can only be obtained with a prescription and treatment should be started by a specialist doctor experienced in the management of Duchenne/Becker muscular dystrophy. 
Predpisovanje in izdaja zdravila Translarna je le na recept, zdravljenje z njim pa mora uvesti zdravnik specialist, ki ima izkušnje z zdravljenjem Duchennove/Beckerjeve mišične distrofije.
Duchenne muscular dystrophy can be caused by a number of genetic abnormalities. 
Duchennovo mišično distrofijo lahko povzročijo številne genetske nepravilnosti.
Translarna works in these patients by enabling the protein-making apparatus in cells to move past the defect, allowing the cells to produce a functional dystrophin protein. 
Zdravilo Translarna pri teh bolnikih deluje tako, da omogoči mehanizmom v celicah, ki sodelujejo pri tvorbi beljakovine, da premostijo okvaro, s čimer omogoči celicam, da izdelajo funkcionalno beljakovino distrofin.
Duchenne muscular dystrophy is a genetic disease that gradually causes weakness and loss of muscle function. 
Duchennova mišična distrofija je genetska bolezen, ki postopoma povzroči šibkost in prenehanje delovanja mišic.
The effect was more pronounced in a subgroup of patients whose ability to walk was worsening, where patients taking 40 mg/kg daily Translarna could walk on average 50 metres more than those taking placebo. 
Učinek je bil izrazitejši v podskupini bolnikov, pri katerih se je zmožnost hoje poslabšala, pri čemer so bolniki, ki so jemali zdravilo Translarna v odmerku 40 mg/kg na dan, lahko prehodili v povprečju 50 metrov več kot tisti, ki so jemali placebo.
For the full list of side effects and restrictions of Translarna, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Translarna glejte navodilo za uporabo.
No improvement was seen with the higher dose (80 mg/kg daily). 
Pri uporabi večjega odmerka (80 mg/kg/dan) niso opazili nobenega izboljšanja.
Translarna is for use in patients whose disease is due to the presence of certain defects (called nonsense mutations) in the dystrophin gene which prematurely stop the production of a normal dystrophin protein, leading to a shortened dystrophin protein that does not function properly. 
Zdravilo Translarna je namenjeno za uporabo pri bolnikih, pri katerih je bolezen posledica prisotnosti določenih okvar (imenovanih nesmiselne mutacije) gena za distrofin, ki predčasno zaustavijo tvorbo normalne beljakovine distrofina, zaradi česar nastane skrajšana oblika beljakovine distrofin, ki ne deluje pravilno.
A small study in children aged 2 to 5 years with Duchenne muscular dystrophy found that the usual dose of Translarna 40 mg/kg daily was sufficient. 
Z manjšo študijo pri otrocih z Duchennovo mišično distrofijo, starih od 2 do 5 let, je bilo ugotovljeno, da zadostuje običajni odmerek zdravila Translarna 40 mg/kg dnevno.
Although an initial analysis of the results of all the data from the study did not show a significant difference in the distances patients in the Translarna and placebo groups could walk, further analyses indicated that walking ability worsened to a lesser extent with 40 mg/kg daily Translarna than with placebo: after 48 weeks of treatment patients receiving 40 mg/kg daily Translarna could walk on average 32 metres more than those given placebo. 
Čeprav prvotna analiza rezultatov vseh podatkov iz študije ni pokazala pomembne razlike med razdaljami, ki so jih lahko prehodili bolniki iz skupine, ki je jemala zdravilo Translarna, in bolniki iz skupine, ki je jemala placebo, so dodatne analize pokazale, da se je zmožnost hoje pri uporabi zdravila Translarna v odmerku 40 mg/kg na dan poslabšala manj kot pri uporabi placeba: po 48 tednih zdravljenja so bolniki, ki so prejemali zdravilo Translarna v odmerku 40 mg/kg na dan, v povprečju lahko prehodili 32 metrov več kot tisti, ki so prejemali placebo.
Patients with Duchenne muscular dystrophy lack normal dystrophin, a protein found in muscles. 
Bolniki z Duchennovo mišično distrofijo imajo pomanjkanje normalnega distrofina, tj. beljakovine, ki je prisotna v mišicah.
How does Translarna work? 
Kako zdravilo Translarna deluje?
In one main study, involving 174 patients aged 5 to 20 years with Duchenne muscular dystrophy who were able to walk, two doses of Translarna (40 mg/kg daily and 80 mg/kg daily) were compared with placebo (a dummy treatment). 
V eni glavni študiji, v katero je bilo vključenih 174 bolnikov z Duchennovo mišično distrofijo, starih od 5 do 20 let, ki so lahko hodili, so dva odmerka zdravila Translarna (40 mg/kg na dan in 80 mg/kg na dan) primerjali s placebom (zdravilom brez zdravilne učinkovine).
How is Translarna used? 
Kako se zdravilo Translarna uporablja?
The European Commission granted a marketing authorisation valid throughout the European Union for Raptiva to Serono Europe Ltd. on 20 September 2004. 
Evropska komisija je dovoljenje za promet z zdravilom Raptiva, veljavno po vsej Evropski uniji, odobrila družbi Serono Europe Ltd. dne 20. septembra 2004.
Patients may inject themselves once they have been trained, if their doctor thinks that this is appropriate. 
Bolniki si lahko zdravilo injicirajo sami, pod pogojem da so bili za to ustrezno usposobljeni, če zdravnik meni, da je to primerno.
In the fifth study, 526 of the 793 patients were ‘high need', since they had failed to respond to or could not take other systemic treatments. 
V peti raziskavi je bilo 526 izmed 793 bolnikov takih z „visoko potrebo“, saj se niso odzvali na ali niso mogli jemati drugih sistemskih zdravil.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) RAPTIVA 
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) RAPTIVA
It is given as a 12-week course, with a first dose of 0.7 mg per kilogram body weight followed by weekly injections of 1.0 mg/kg. 
Daje se 12 tednov, začetni odmerek je 0,7 mg na kilogram telesne mase, čemur sledijo tedenske injekcije v odmerku 1,0 mg/kg.
The main measure of effectiveness was the proportion of patients who ‘responded' to treatment after 12 weeks, meaning that symptom scores improved by 75% or more. 
Glavno merilo učinkovitosti je bil delež bolnikov, ki so se po 12 tednih odzvali na zdravljenje, kar je pomenilo, da so se ocene simptomov izboljšale za 75 % ali več.
The Committee for Medicinal products for Human Use (CHMP) noted that psoriasis was more severe in ‘high-need' patients, and that the effectiveness of Raptiva is relevant for these patients. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je upošteval, da je bila psoriaza hujša pri bolnikih z „visoko potrebo“ in da je učinkovitost zdravila Raptiva pomembna za te bolnike.
The Committee recommended that Raptiva be given marketing authorisation. 
Odbor je zato priporočil, da se za zdravilo Raptiva odobri dovoljenje za promet.
How has Raptiva been studied? 
Kako je bilo zdravilo Raptiva raziskano?
What benefit has Raptiva shown during the studies? 
Kakšne koristi je zdravilo Raptiva izkazalo med raziskavami?
A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on the surface of cells in the body. 
Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo oblikovano tako, da prepozna in se veže na specifično strukturo (imenovano antigen), ki se nahaja na površini celic v telesu.
Raptiva is given by injection under the skin. 
Zdravilo Raptiva se daje z injekcijo pod kožo.
As LFA-1 is important in helping the lymphocytes to stick to cells in the skin, efalizumab reduces the inflammation in the skin that causes psoriasis. 
Ker LFA-1 pomembno pomaga limfocitom, da se vežejo na celice v koži, efalizumab zmanjšuje vnetje kože, ki povzroča psoriazo.
Raptiva has been studied in five main studies involving over 3,000 patients with moderate to severe plaque psoriasis. 
Zdravilo Raptiva so preučevali v petih glavnih študijah z več kot 3000 bolniki z zmerno do hudo psoriazo s plaki.
Raptiva was more effective than placebo at improving the symptoms of psoriasis. 
Zdravilo Raptiva je bilo pri izboljšanju simptomov psoriaze učinkovitejše od placeba.
Looking only at the ‘high need' patients in this study, 30% of those receiving Raptiva responded to treatment, compared with 3% of those receiving 
Če upoštevamo le bolnike z „visoko potrebo“ iz te študije, se je na zdravljenje odzvalo 30 % izmed tistih, ki so prejemali zdravilo Raptiva, v primerjavi s 3 % bolnikov, ki so prejemali placebo.
It contains the active 
Vsebuje zdravilno
In the fifth study, overall, 166 (31%) of the 529 patients receiving Raptiva responded to treatment, compared with 11 (4%) of the 264 receiving placebo. 
V peti študiji se je na zdravljenje odzvalo skupaj 166 (31 %) izmed 529 bolnikov, ki so prejemali zdravilo Raptiva, v primerjavi z 11 (4 %) izmed 264 bolnikov, ki so prejemali placebo.
Efalizumab has been designed to bind to part of a protein called LFA-1 on the surface of lymphocytes, a type of white blood cell that is involved in the inflammation process. 
Efalizumab je zasnovan tako, da se veže na del beljakovine, imenovane LFA-1, na površini limfocitov, tj. na vrsto belih krvničk, ki sodeluje pri vnetnem procesu.
Looking at the results of the first four studies taken together, 320 (26%) of the 1,213 patients receiving 1.0 mg/kg Raptiva per week responded to treatment, compared with 25 (4%) of the 715 receiving placebo. 
Če pogledamo rezultate prvih štirih študij skupaj, ugotovimo, da se je na zdravljenje odzvalo 320 (26 %) izmed 1213 bolnikov, ki so prejemali 1,0 mg/kg zdravila Raptiva tedensko, v primerjavi s 25 (4 %) izmed 715 bolnikov, ki so prejemali placebo.
The most common side effects with Raptiva (seen in more than 1 patient in 10) are mild to moderate flu-like symptoms including headache, fever, chills, nausea (feeling sick), myalgia (muscle pain), and leucocytosis and lymphocytosis (increased white blood cell counts). 
Najpogostejši neželeni učinki pri jemanju zdravila Raptiva (opaženi pri več kot 1 izmed 10 bolnikov) so blagi do zmerni gripi podobni simptomi, kot so glavobol, povišana telesna temperatura, mrzlica, navzeja (slabost), mialgija (bolečina v mišicah) ter levkocitoza in limfocitoza (zvišana koncentracija belih krvničk).
It should also not be used in patients who have had cancer, who have active tuberculosis or another severe infection, who have other types of psoriasis, or who have low levels of 
Prav tako ga ne smejo uporabljati bolniki, ki so imeli raka, ki imajo aktivno tuberkulozo ali druge hude okužbe, druge oblike psoriaze ali oslabljen imunski sistem.
Raptiva treatment should be initiated by a doctor who specialises in dermatology (the treatment of skin conditions). 
Zdravljenje z zdravilom Raptiva mora uvesti zdravnik, specializiran za dermatologijo (zdravljenje kožnih obolenj).
The active substance in Raptiva, efalizumab, is a monoclonal antibody. 
Zdravilna učinkovina zdravila Raptiva, efalizumab, je monoklonsko protitelo.
In all studies, the effectiveness of Raptiva was compared with that of placebo (a dummy treatment). 
V vseh študijah so učinkovitost zdravila Raptiva primerjali z učinkovitostjo placeba (zdravila brez zdravilne učinkovine).
Raptiva should not be used in people who may be hypersensitive (allergic) to efalizumab or any of the other ingredients. 
Zdravila Raptiva ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) efalizumab ali katero koli drugo sestavino zdravila.
Raptiva should be used with caution in patients who have problems with their liver or 
Zdravilo Raptiva je treba pri bolnikih, ki imajo težave z jetri ali ledvicami, uporabljati previdno.
Raptiva is used for the treatment of adults with moderate to severe chronic (long-term) plaque psoriasis (a disease causing red, scaly patches on the skin). 
Zdravilo Raptiva se uporablja za zdravljenje odraslih z zmerno do hudo kronično (dolgotrajno) psoriazo (luskavico) s plaki (bolezen, ki povzroča rdeče, luskaste spremembe na koži).
It is used in patients who have failed to respond to or cannot take other systemic (whole-body) treatments for psoriasis, including ciclosporin, methotrexate and PUVA (psoralen ultraviolet-A). 
Uporablja se pri bolnikih, ki se ne odzivajo na ali ne morejo jemati drugih sistemskih zdravil (zdravil, ki delujejo na celotno telo) za psoriazo, vključno s ciklosporinom, metotreksatom in PUVA (psoralen v kombinaciji z obsevanjem z UVA žarki).
PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen' before being exposed to ultraviolet 
PUVA je vrsta zdravljenja, pri katerem prejme bolnik, preden je izpostavljen ultravijolični svetlobi, zdravilo, ki vsebuje spojino psoralen.
Raptiva is a powder and solvent that are made up into a solution for injection. 
Zdravilo Raptiva je prašek in vehikel za pripravo raztopine za injiciranje.
Therefore, the Committee decided that Raptiva's benefits are greater than its risks for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contra-indication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA. 
Odbor je zato odločil, da so koristi zdravila Raptiva pri zdravljenju odraslih bolnikov z zmerno do hudo kronično psoriazo s plaki, ki se ne odzivajo na druga sistemska zdravljenja, vključno s ciklosporinom, metotreksatom in PUVA, oziroma imajo zanje kontraindikacije ali jih ne prenašajo, večje od z njim povezanih tveganj.
This improves 
To izboljša simptome bolezni.
The full EPAR for Raptiva can be found here. 
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Raptiva je na voljo tukaj.
For the full list of all side effects reported with Raptiva, see the Package Leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila
The studies included patients who had not taken other treatments for psoriasis in the past, as well as those who had taken other treatments. 
Rezultati so bili pri bolnikih, ki so predhodno prejemali sistemska zdravila za psoriazo, podobni kot pri bolnikih, ki teh zdravil niso prejemali.
Therapy should only be continued in patients who have responded to treatment. 
Maksimalni posamični odmerek je 200 mg. Zdravljenje se sme nadaljevati samo pri bolnikih, ki so se odzvali na zdravljenje.
The main measure of effectiveness was the average change in the blood pressure. 
Glavno merilo učinkovitosti je bila povprečna sprememba krvnega tlaka.
The European Commission granted a marketing authorisation valid throughout the European Union for Exforge HCT on 16 October 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Exforge HCT, veljavno po vsej Evropski uniji, odobrila dne 16. oktobra 2009.
The full EPAR for Exforge HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Exforge HCT je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
amlodipine / valsartan / hydrochlorothiazide 
amlodipin/valsartan/hidroklorotiazid
Because the combination of the three active substances has been in use for a number of years, the company presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets. 
Ker se kombinacija treh zdravilnih učinkovin uporablja že vrsto let, je družba predstavila študije, ki kažejo, da se tableta, ki vsebuje vse tri učinkovine, v telesu absorbira enako kot tablete z ločenimi učinkovinami.
This is a summary of the European public assessment report (EPAR) for Exforge HCT. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Exforge HCT.
It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg. 
Na voljo je v obliki tablet, ki vsebujejo amlodipin, valsartan in hidroklorotiazid v naslednjih količinah: 5/160/12,5 mg, 10/160/12,5 mg, 5/160/25 mg, 10/160/25 mg in 10/320/25 mg.
For more information about treatment with Exforge HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Exforge HCT preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Valsartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II. 
Valsartan je antagonist receptorja za angiotenzin II, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
Exforge HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning. 
Zdravilo Exforge HCT se jemlje peroralno, in sicer se zaužije ena tableta enkrat na dan ob isti uri, če je le mogoče, zjutraj.
The CHMP therefore decided that Exforge HCT's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Exforge HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone. 
Kombinacija treh zdravilnih učinkovin ima aditiven učinek, saj zniža krvni tlak bolj kot vsako posamezno zdravilo posebej.
The main study showed the benefit of the highest strength of Exforge HCT in lowering the blood pressure. 
Glavna študija je pokazala koristnost uporabe največjega odmerka zdravila Exforge HCT pri zniževanju krvnega tlaka.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Exforge HCT, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Amlodipine is a ‘calcium channel blocker'. 
Amlodipin je zaviralec kalcijevih kanalčkov.
The three active substances in Exforge HCT are anti-hypertensive medicines that are already in use in the European Union (EU). 
Tri zdravilne učinkovine v zdravilu Exforge HCT so zdravila proti zvišanemu krvnemu tlaku, ki se že uporabljajo v Evropski uniji (EU).
Exforge HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide. 
Zdravilo Exforge HCT se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih, pri katerih je krvni tlak že ustrezno uravnan z uporabo kombinacije amlodipina, valsartana in hidroklorotiazida.
The most common side effects with Exforge HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention). 
Najpogostejši neželeni učinki zdravila Exforge HCT (opaženi pri 1 do 10 bolnikih od 100) so hipokaliemija (nizka raven kalija v krvi), omotica, glavobol, hipotenzija (nizek krvni tlak), dispepsija (zgaga), polakisurija (neobičajno pogosto uriniranje), utrujenost in edem (zadrževanje tekočine).
Exforge HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide. 
Exforge HCT je zdravilo, ki vsebuje tri zdravilne učinkovine amlodipin, valsartan in hidroklorotiazid.
The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Exforge HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively. 
Povprečno znižanje krvnega tlaka je bilo okrog 39,7/24,7 mmHg pri bolnikih, ki so prejemali zdravilo Exforge HCT, v primerjavi z 32/19,7 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/hidroklorotiazid, 33,5/21,5 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/amlodipin, in 31,5/19,5 mmHg pri bolnikih, ki so prejemali kombinacije hidroklorotiazid/amlodipin.
For all doses, Exforge HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken seperately. 
Pri vseh odmerkih je zdravilo Exforge HCT izpolnilo tudi zahteve, s katerimi je bilo dokazano, da je primerljivo s kombinacijami posameznih zdravilnih učinkovin, vzetih ločeno.
The daily dose of Exforge HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide. 
Dnevni odmerek učinkovin zdravila Exforge HCT ne sme biti večji od 10 mg amlodipina, 320 mg valsartana in 25 mg hidroklorotiazida.
What benefit has Exforge HCT shown during the studies? 
Kakšne koristi je zdravilo Exforge HCT izkazalo med študijami?
Treatment with the highest strength of Exforge HCT was more effective at treating hypertension than dual combinations containing any of the two active substances. 
Zdravljenje z največjim odmerkom zdravila Exforge HCT je bilo pri zdravljenju hipertenzije učinkovitejše od zdravljenja z dvojnimi kombinacijami, ki so vsebovale po dve zdravilni učinkovini.
For the full list of all side effects reported with Exforge HCT, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Exforge HCT, glejte navodilo za uporabo.
The dose of Exforge HCT to be used is the same as the doses of three individual active substances that the patient was taking before. 
Odmerek učinkovin zdravila Exforge HCT mora biti enak odmerkom treh posameznih zdravilnih učinkovin, ki jih je bolnik prejemal pred tem.
By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to reduce. 
Ker valsartan ustavi njegovo delovanje z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, hormonu prepreči učinkovanje, zaradi česar se krvne žile lahko razširijo, krvni tlak pa zniža.
It works by increasing urine output, reducing the volume of fluid in the blood and lowering the blood pressure. 
Deluje tako, da poveča izločanje seča, zaradi česar se zmanjša količina tekočine v telesu in zniža krvni tlak.
Exforge HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Exforge HCT. 
Zdravila Exforge HCT ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilne učinkovine, druge sulfonamide, derivate dihidropiridina ali katero koli drugo sestavino zdravila
By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and helps the blood vessel walls to relax and widen, thereby reducing blood pressure. 
Amlodipin z zmanjšanjem pretoka kalcija v celice prepreči njihovo krčenje in pomaga pri sproščanju in širjenju sten žil ter tako znižuje krvni tlak.
Other information about Exforge HCT 
Druge informacije o zdravilu Exforge HCT